Materials and methods Eligibility The study was approved by the Institutional Review Board at Oregon Health & Science University (OHSU) and patient informed consent was waived. Medical records from selleckbio patients with esophageal malignancies treated with NAC followed by esophagectomy at OHSU from September 1996 to May 2011 were selected from a prospective esophageal registry and retrospectively reviewed. Eligible patients included

those with stage I-III esophageal cancer deemed medically operable by an experienced general or thoracic surgeon or medically inoperable who went on to receive NAC Inhibitors,research,lifescience,medical and were subsequently deemed operable. Patients with recurrent or metastatic disease, a history of previous selleck chemicals malignancy, and as those unable to undergo chemoradiotherapy were excluded from the study. A cohort of 106 consecutive patients formed the basis of this selection. Treatment plans Patients who underwent NAC were treated with platinum-based Inhibitors,research,lifescience,medical chemotherapy (including cisplatin, oxaliplatin, or carboplatin) together with 5-fluorouracil (5-FU) or capecitabine Inhibitors,research,lifescience,medical concurrently with radiation.

Additionally, 17 patients received a mitotic inhibitor (paclitaxel or docetaxel) in their regimen. Notable exceptions include six patients who received platinum-based therapy but did not receive 5-FU or capecitabine and a single patient who received paclitaxel and 5-FU but did Inhibitors,research,lifescience,medical not tolerate a platinum-based agent. The majority of patients received 50.4 Gy radiation by standard fractionation, although cumulative dose ranged from 36-63 Gy. Surgical resection was performed via a transhiatal, Ivor-Lewis, or 3-field approach as previously described (14,15). Eligible patients underwent chemoradiotherapy at OHSU as well as local community hospitals, however all surgical resections were performed at OHSU by experienced general, thoracic, Inhibitors,research,lifescience,medical and/or oncologic surgeons. Staging and pathology Prior to administering NAC, all patients were staged by endoscopic ultrasound

(EUS), computed tomography (CT), or positron emission tomography (PET). Following NAC and esophagectomy, post-operative pathological staging was compared to initial staging to analyze Carfilzomib the effect of NAC and subsequent down- or upstaging. In this study, an R0 resection is defined as a curative resection, with microscopic examination of margins demonstrating absence of tumor cells while a R1 resection demonstrates the presence of tumors cells at the margin of resection. A pCR is defined as the absence of any residual tumor cells during histologic examination. Survival analysis and statistical methods Clinical follow up and the Social Security Death Index were used to determine length of survival for each patient. OS was analyzed by the Kaplan Meier method and survival curves were generated using R statistical software (version 2.13.1, R Development Core Team, Vienna, Austria).